Podcasts about eular

Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life Spondyloarthritis Panel: Eular 2025

Digital Behavioural Therapy for Persistent Pain in Axial Spondyloarthritis There's an App for That (and it works): the AXIA RCT

Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what's new from EULAR 2025 and what it means for improving patient outcomes.

Eular 2025 PsA Topic Panel Assessment of Peripheral Arthritis in Spondyloarthritis IL-17 inhibitors - Novel Drugs IL17 inhibitors - Long-term Extensions and Uveitis IL17 inhibitors - STAMP T2T and Combinations Using AI for Reading PET/CT in Rheumatoid Arthritis

Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don't miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what's next for RA care.

EULAR 2025 - Day 1 podcasts Sonelokimab in PsA Seronegative Arthritis Breakthroughs Using Combination csDMARDs in PsA Deucravacitinib's Place in the PsA Treatment Algorithm?

Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact GLP 1 Receptor Agonists in axSpA Patients Jekyll and Hyde: which RA-ILD is it? RA treatment: A Constant State of Evolution

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Emerging Therapies in Axial Spondyloarthritis Chronic Pain in AxSpA Beyond Fibromyalgia Novel Therapies in Axial Spondyloarthritis JAK Inhibitors: The Latest from the JAK-pot Study Does Abatacept Buy You Time Off RA? How to Properly Use Steroids in Early RA: Oral vs Parenteral All Rheumatoid Arthritis is Not the Same

Deucravacitinib's Place in the PsA Treatment Algorithm? Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-axSpA JAK Safety Update Why is RA Difficult to Treat? DMARD Combinations in RA Treatment Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data ALTO: Long-term Outcomes of APIPPRA

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the fourth day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.  

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 4 of EULAR 2025 (Saturday, June 14).

Seronegative Arthritis Breakthroughs Jokes Aside: The Impact of Laughter in RA The Impact of Biologics on Methotrexate Adherence Thoughtful, Effective RA Care Should be Guided by Need —Not Age Sonelokimab in PsA Using Combination csDMARDs in PsA

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the third day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.  

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 3 of EULAR 2025 (Friday, June 13).

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the first day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 2 of EULAR 2025 (Thursday, June 12).

Efficacy and Safety of Xeligekimab in AS Who/When to Treat Clinically Suspect Arthralgia

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 1 of EULAR 2025 (Wednesday, June 11).

Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they guide you through what they are most looking forward to in RA, PsA, and axSpA at EULAR 2025, so that you can better plan your time at what will be a busy and exciting congress.

Autrefois appelée la « maladie des rois », la goutte est une pathologie causée par un excès d'acide urique. Sans prise en charge adéquate, elle peut avoir d'importants effets sur la qualité de vie des patients. Afin de faire le point sur cette maladie, Trait pharmacien reçoit Marjolaine Giroux, pharmacienne au CIUSSS de l'Est-de-l'Île-de-Montréal et membre du Regroupement de pharmaciens experts en néphrologie de l'A.P.E.S. Références : FitzGerald JD et coll. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020;72:744-60. Richette P et coll. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29-42. KDIGO CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105:S117-314.

In this compelling episode of Inside GRAPPA, host Dr. Hanna Johnsson, a rheumatologist based in Scotland, leads an important conversation on one of the most pressing issues in psoriatic arthritis (PsA) care: what truly makes a case difficult to treat or complex to manage?Dr. Johnsson is joined by two experts deeply embedded in the GRAPPA initiative to define these concepts:Dr. Fabian Proft, Head of the Division of Rheumatology at Charité Berlin, Germany, and long-time GRAPPA contributor.Dr. Shikha Singla, Assistant Professor of Medicine at the Medical College of Wisconsin, who brings firsthand experience from her combined rheum-derm clinic.Together, they unpack the background, progress, and patient-centered approach of the Difficult-to-Treat (D2T) and Complex-to-Manage PsA Project.✅ HighlightsClearer definitions aim to improve care for patients with persistent symptoms despite treatment“Difficult to treat” focuses on ongoing inflammation; “complex to manage” accounts for non-inflammatory factorsA global literature review revealed inconsistent criteria in defining treatment challengesSurveys of clinicians and patients shaped a more inclusive, consensus-driven frameworkNew definitions to be presented at EULAR—marking a major milestone in PsA research⏱ Timestamps00:00 – Introduction to the episode and today's topic00:36 – Guest introductions: Dr. Fabian Proft and Dr. Shikha Singla01:00 – Fabian on the need for better definitions and understanding treatment failure04:12 – Defining the terms: inflammation vs. non-inflammatory drivers of disease burden05:15 – Why “complex to manage” is more appropriate than “difficult patient”06:00 – How terminology shapes perceptions and supports more empathetic care06:42 – Scoping literature review: methods and inconsistencies in existing definitions07:57 – Healthcare provider survey: over 200 responses, strong support for two definitions09:12 – Patient survey: nearly 600 responses and insights into global experiences10:21 – Patient-reported challenges: joint pain, fatigue, medication side effects11:54 – Cultural and social factors influencing patient experience12:39 – The Delphi process and achieving expert consensus13:15 – Project milestones: EULAR submission and upcoming publications

Als reumatologen hebben we er steeds vaker mee te maken, bijwerkingen van checkpoint inhibitors. Voor Gewrichtige Gesprekken (laatste aflevering van seizoen 2!) spraken Nienke Lesuis en Caroline Aalbers met Karen Visser, reumatoloog en mede-auteur van het EULAR points to consider artikel over dit onderwerp. Naast een overview van het artikel krijg je ook uitleg over de achtergrond van deze groep aandoeningen en praktische tips voor in de spreekkamer. En mocht je je afvragen wat Karen in haar vrije tijd doet, vooral ook even luisteren naar de Duivelse Dilemma's! 

What does it mean to be diagnosed with undifferentiated disease (UD)? In this episode, Tiffany Westrich-Robertson, AiArthritis CEO and founder, unpacks this complex diagnosis, sharing her personal journey from being a mystery patient to receiving a UCTD diagnosis. Tiffany explains how undifferentiated disease fits into the autoimmune.autoinflammatory spectrum, its implications for treatment, and why early intervention is critical. Join us on this episode to explore what undifferentiated disease means, how early treatment can improve outcomes, and the latest research shaping diagnosis and care. Tell us YOUR undifferentiated disease story: https://bit.ly/3EfuWsT Check out our social media channels for posts about UD and weigh in Sign up for our AiArthritis Research Database, where we are studying UD at www.aiarthritis.org/database Donate to Support the Show: www.aiarthritis.org/donate Episode Highlights: Learn more about undifferentiated disease, including why it's so important to know it can be the final diagnosis OR it could branch off to a “full blown” autoimmune or autoinflammatory disease, including one of ours that include inflammatory arthritis as a major clinical component. Either way, UD IS a real diagnosis. Explore the connection between undiagnosed “mystery patients”, an undifferentiated diagnosis, and how UCTD and other undifferentiated conditions fit into the spectrum of autoimmune and autoinflammatory diseases. Understand the importance of early intervention and how it can lead to remission and improved outcomes. Discover the role of biomarkers, precision medicine, and risk stratification in guiding treatment plans. Hear how AiArthritis is advancing research and offering resources to help patients navigate undifferentiated disease.   Links & Resources Explore more from the “Go With Us to Conferences” program: www.aiarthritis.org/conferences Early Symptoms of AiArthritis Study: https://www.aiarthritis.org/Early-Symptoms-Study Go With Us to EULAR 2023 - Ig-G4, UCTD, RMDs and the Brain: https://www.youtube.com/watch?v=1w2Ouk-ItFk&t=264s Volunteer with AiArthritis : https://bit.ly/AiArthritisVolunteerApp   Follow AiArthritis on all social media platforms @IFAiArthritis Sign up for our Monthly AiArthritis Voices 360 Talk Show newsletter! HERE

In this episode, our co-hosts bring you an exclusive look into the AiArthritis “Go With Us!” to Conferences program. We dive deep into EULAR 2024, the European Rheumatology Research Conference, where patients and co-hosts reveal groundbreaking advancements in AiArthritis research. Discover the latest on CAR-T therapy, innovative pain management tailored for patients, the role of opioids in addressing pain and fatigue, and practical strategies for battling brain fog. Gain valuable insights and practical advice from fellow patients and experts. Don't miss this episode packed with cutting-edge information!   If you're eager for more, join us for our next journey to the ACR conference in November. Visit AiArthritis.org/conferences for more details and to sign up! Episode Highlights Overview of the Go With Us to Conferences program, which allows patients to virtually join and learn from major rheumatology conferences like EULAR and ACR.  Tiffany, CEO and person living with non-radiographic axial spondyloarthritis, discusses CAR-T therapy and its potential to achieve remission in autoimmune diseases, particularly in lupus patients. Deb, AiArthritis volunteer and person living with rheumatoid arthritis, presents on patient-tailored pain management, emphasizing multi-dimensional approaches to address different types of pain. Becky, AiArthritis volunteer and person living with Sjogren's Disease, explores the relationship between fatigue, pain, and opioids, highlighting the challenges of treating these symptoms in autoimmune patients. Leila, AiArthritis Health Education Manager and person living with Lupus Nephritis and Sjogren's Disease, covers cognitive dysfunction (brain fog), offering strategies for managing this common but under-discussed symptom in autoimmune diseases. Volunteer with AiArthritis : https://bit.ly/AiArthritisVolunteerApp Donate to Support the Show: https://www.aiarthritis.org/donate  Follow AiArthritis on all social media platforms @IFAiArthritis Sign up for our Monthly AiArthritis Voices 360 Talk Show newsletter! HERE   Resources & Links: Join the Go With Us Program for ACR in November: https://aiarthritis.org/conferences Connect with our Co-Hosts: Tiffany is the CEO at AiArthritis (International Foundation for Autoimmune & Autoinflammatory Arthritis) and uses her professional expertise in mind-mapping and problem solving to help others, like her, who live with AiArthritis diseases work in unison to identify and solve unresolved community issues.   Leila is the Health Education Manager at the International Foundation for AiArthritis. She is a person living with Lupus Nephritis and Sjögren's Syndrome. She is passionate about inclusion and diversity in health education and meeting individuals where they are at in order to learn in a way that resonates with them.    Deb Constien is a medically retired Registered Dietitian and a Representative for AiArthritis with Rheumatoid Arthritis. Deb is also on the Advisory Council for WREN- Wisconsin Research Education Network and a Patient Family Advisor- PFA on an International PCORI research study for ACP- Advanced Care Planning.   Becky Hosey is an AiArthritis volunteer, a healthcare professional, and also a person living with Sjogren's disease.

Moderated by Dr. Jack Cush and Featuring Drs. Eric Ruderman, Antoni Chan, and Peter Nash

Featuring Drs. Jack Cush, Yuz Yusof, and Andrea Fava

Moderated by Dr. Jack Cush and featuring Drs. Aurelie Najm, David Liew and Jonathan Kay

Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. PsA Treatment: is Earlier Better? Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria. Transition from Psoriasis to PsA: Can we Prevent It? Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. PsA Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. Axial & Psoriatic Disease Dr. Peter Nash at Eular 2024 in Vienna, Austria. Difficult to Treat Psoriatic Arthritis Dr. Peter Nash reports at Eular 2024 in Vienna, Austria. Predictors of Treatment Response in Psoriatic Arthritis Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:  POS 0990 POS 0992 POS 0266 Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.  

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.  

Mechanistic Promise in RA Doesn't Always Mean Actual Gain Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria. The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309. A Step Closer to Identifying Phenotypes of RA ILD Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Predicting Palindromic Prognosis Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. Abatacept Misses on Shingrix Response Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria. Artificial Intelligence Detection of CPPD on Hand Radiographs Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria. Cognitive Function in Older Adults with Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. Difficult-to-treat Rheumatoid Arthritis Validation of the EULAR Definition Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria. DMARDs and Herpes Zoster Vaccination To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Inspirations About RA-ILD Dr. Jonathan Kay discusses abstracts POS0070, POS0043 and POS0022 presented at the Eular 2024 meeting in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. Digital Rheumatology Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria. Drug-resistant RA Does Blinatumomab BiTE? Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.  

Does B Cell Depletion Matter? Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria. 3 Big Lupus Themes from EULAR 2024 Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.  POS0732 OP0255 Voclosporin and Steroids in Lupus Nephritis Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. Cognitive Function in Older Adults with Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. Does Withdrawing Steroids Increase Flares in SLE? Dr. Janet Pope reports on abstract OP0180 presented at Eular 2024 in Vienna, Austria. Tapering Treatment for Lupus Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus. The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity at Eular 2024 in Vienna, Austria. We've Got to Talk about CAR T cells Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.    

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter? Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab Does Telemonitoring in SpA Work? Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria. Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria. Treat to Target Outcomes in Early AxSpA Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria. Early Diagnosis of Axial Spondyloarthritis Dr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria. Imaging in Axial Spondyloarthritis Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.

Dr. Peter Nash reports at Eular 2024 in Vienna, Austria.

EULAR 2024 RECAP DAY 3 Moderated by Dr. Jack Cush with Drs. Bella Mehta and Antoni Chan.

Dr. Peter Nash at Eular 2024 in Vienna, Austria.

Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.

Axial & Psoriatic Disease Dr. Peter Nash at Eular 2024 in Vienna, Austria. Difficult to Treat Psoriatic Arthritis Dr. Peter Nash reports at Eular 2024 in Vienna, Austria. Predictors of Treatment Response in Psoriatic Arthritis Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:  POS 0990 POS 0992 POS 0266 Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. Digital Rheumatology Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria. Drug-resistant RA Does Blinatumomab BiTE? Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria. Early Diagnosis of Axial Spondyloarthritis Dr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria. Imaging in Axial Spondyloarthritis Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.  

Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:  POS 0990 POS 0992 POS 0266

Moderated by Dr. Jack Cush and featuring Dr. Aurelie Najm and Dr. David Liew Recorded June 15, 2024

Dr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria.